
|Videos|March 30, 2018
Dr. Matulonis Discusses Mirvetuximab Soravtansine Plus Pembrolizumab in Ovarian Cancer
Author(s)Ursula A. Matulonis, MD
Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses initial safety and activity findings from a phase IB escalation study of mirvetuximab soravtansine, a folate receptor alpha-targeting antibody-drug conjugate, with pembrolizumab (Keytruda) in patients with platinum-resistant epithelial ovarian cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































